Dr. Alan Charles Carver, MD

Dr. Carver practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Carver's NPI, 1245200815, was assigned on January 25, 2006. Dr. Carver graduated from Boston University School Of Medicine in 1995. Dr. Carver holds New York license 204817.

Dr. Carver's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Carver's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Carver to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Carver practices. Vendor and product names are available with a free account.

Neurology is Dr. Carver's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Carver is board certified in hospice and palliative medicine by the American Board of Internal Medicine. Dmand AI has Dr. Carver's licenses on file in 4 states: New York, Florida, Connecticut and New Jersey.

Dmand AI lists cerebrovascular disease, epilepsy, essential tremor, fibromyalgia and chronic pain, head injury, hereditary polyneuropathy, lower back pain and migraine and chronic headache among the conditions Dr. Carver treats.

CMS data shows 433 Medicare services from Dr. Carver across 6 procedure codes in 2024, for 264 Medicare patients. Medicare paid $39,440 for them.

CMS counts 264 Medicare patients who saw Dr. Carver in 2024. The largest group is 65 to 74, with 115 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 18% are also on Medicaid. Their average risk score is 2.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Carver's median patient age at 68, with 64% women.

In 2024, Dr. Carver wrote 1,552 Medicare Part D claims for 199 patients. 94% of them were for generic drugs. CMS names the drug for 1,333 of them, across 39 drugs with 11 or more claims each, at $109,144 in total drug cost. In 2023, CMS named 1,107 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Carver for performance year 2024, reported as part of a group. Dr. Carver accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Carver as offering telehealth.

Dmand AI links 15 papers to Dr. Carver, published from 2012 to 2024. The most frequent topics are Palliative Care, Brain Neoplasms and Terminal Care. Dr. Carver has published most often in Neurooncol Pract. Dr. Carver's most frequent co-authors are Eli Louis Diamond, MD, Ghassan K. Abou-Alfa, MD and Volkan Beylergil, MD.

Dmand AI lists 3 awards for Dr. Carver, most recently Top Doctors: New York Metro Area in 2016. Dr. Carver serves on MSKCC Ethics Consultation Service, MSKCC Quality Assurance Committee and Neurology Dept. Quality Assurance Committee.

Dr. Carver graduated from Boston University School Of Medicine in 1995. Dr. Carver is a member of AAHPM, AAN and Society for Neuro-Oncology.

Dr. Carver is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.